Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A Roadmap [0.03%]
微小残留病灶作为加速批准多发性骨髓瘤新药的早期替代终点的路线图
Ola Landgren,Sean M Devlin
Ola Landgren
Improvements in multiple myeloma (MM) treatments have extended patient survival to a decade or more. Treatment response rates >90% have introduced new challenges for drug development, including a need for early endpoints with greater sensit...
CD33-CD123 IF-THEN gating reduces toxicity while enhancing the specificity and memory phenotype of AML-targeting CAR-T cells [0.03%]
基于CD33-CD123的IF-THEN门控技术可在提高AML靶向CAR-T细胞特异性及记忆表型的同时降低其毒性
Samy Jambon,Jianping Sun,Shawn Barman et al.
Samy Jambon et al.
CAR T-cell therapy has remarkably succeeded in treating lymphoblastic leukemia. However, its success in AML remains elusive due to the risk of on-target off-tumor toxicity to hematopoietic stem and progenitor cells (HSPC) and insufficient T...
AACR Cancer Progress Report Steering Committee
AACR Cancer Progress Report Steering Committee
Recent advancements in clinical tools for blood cancers are highlighted in this article, adapted from the 14th edition of the annual AACR Cancer Progress Report (https://cancerprogressreport.aacr.org/progress/) to the US Congress and the pu...
Susan Bal,Luciano J Costa
Susan Bal
Among patients with poly-refractory myeloma, autologous chimeric antigen receptor T-cell therapy offers exceptional promise. With the availability of bispecific antibodies, a total immunotherapeutic strategy in combination with chimeric ant...
Hannah Goulart,Hagop Kantarjian,Naveen Pemmaraju et al.
Hannah Goulart et al.
In recent years, there has been tremendous interest surrounding the integration of venetoclax into both non-intensive and intensive chemotherapy regimens for AML. However, with this increasing utilization of venetoclax, considerable questio...
Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma [0.03%]
双特异性抗体作为CAR-T细胞治疗复发/难治性多发性骨髓瘤的桥梁疗法
David Fandrei,Sabine Seiffert,Michael Rade et al.
David Fandrei et al.
Establishing a strategy for sequencing of T cell redirecting therapies for relapsed/refractory multiple myeloma (RRMM) is a pressing clinical need. We longitudinally tracked the clinical and immunological impact of bispecific T cell engagin...
Inés Fernández-Maestre,Sheng F Cai,Ross L Levine
Inés Fernández-Maestre
The development of myeloid malignancies is influenced by a range of cell-intrinsic and cell-extrinsic factors, which can be conceptualized using the hallmarks of cancer. Although many facets of myeloid transformation are similar to those in...
Therapy-Related Myeloid Neoplasms: Complex Interactions among Cytotoxic Therapies, Genetic Factors, and Aberrant Microenvironment [0.03%]
细胞毒性治疗、遗传因素和异常微环境在治疗相关骨髓瘤中的复杂相互作用
Deepak Singhal,Monika M Kutyna,Christopher N Hahn et al.
Deepak Singhal et al.
Therapy-related myeloid neoplasm (t-MN), characterized by its association with prior exposure to cytotoxic therapy, remains poorly understood and is a major impediment to long-term survival even in the era of novel targeted therapies due to...
T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma: Optimal Dosing Schedule and Duration of Treatment [0.03%]
靶向T细胞的双特异性抗体在多发性骨髓瘤治疗中的最佳给药方案和疗程研究
Niels W C J van de Donk,Leo Rasche,Surbhi Sidana et al.
Niels W C J van de Donk et al.
T cell-redirecting bispecific antibodies (BsAb) induce significant responses in heavily pretreated multiple myeloma. BsAbs are currently administered in a dose-dense manner until disease progression. However, continuous therapy is associate...
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes [0.03%]
DNA修复基因的致病变异与多发性骨髓瘤风险和预后有关
Santiago Thibaud,Ryan L Subaran,Scott Newman et al.
Santiago Thibaud et al.
First-degree relatives of patients with multiple myeloma are at increased risk for the disease, but the contribution of pathogenic germline variants (PGV) in hereditary cancer genes to multiple myeloma risk and outcomes is not well characte...